Research Article
Volume 10:5, 2020
DOI: 10.37421/2161-105X.2020.10.510

Journal of
Pulmonary & Respiratory Medicine

ISSN: 2161-105X

Open Access

A Comparison of Effectiveness of Dual and Triple Dose Therapy in COPD

Mohit Kalra*, Ayushma Karmacharya, Shabnam Thakur and Narender Yadav

School of Pharmaceutical Sciences, Apeejay Stya University, Sohna-Palwal Road, Gurgaon, Haryana, India

Abstract

Chronic obstructive pulmonary disease (COPD) has turned out to be the third driving reason of death worldwide today. The pharmacological drugs accessible to treat the COPD patient have expanded in the course of last decade. Patient with advance COPD are particularly at risk of poor result and present trouble on medical services. Combination of bronchodilator especially muscarinic antagonist (LAMA) and B2-agonist (LABA) and combination of B2- agonist and inhaled corticosteroid (ICS) are recommended for patient with moderate COPD, whereas combination of muscarinic antagonist, B2-agonist and inhaled corticosteroid are recommended during severe COPD according to guidelines. They can possibly show additive and synergistic bronchodilation over either pharmacology alone. In the current manuscript, we have extracted data for analysis to compare disease progression in patient those receiving dual bronchodilation with a LABA plus a LAMA as a fixed or free combination (dual bronchodilation) and those receiving triple therapy of a LABA plus a LAMA and an ICS. Given the results from studies, our speculation was that: proposed efficacy and safety of triple dose therapy was more efficient and greater as compared to dual bronchodilation.

Keywords: COVID-19 • Emphysema • COPD Treatment • Bronchodilator • Forced Expiratory Volume

Introduction

Globally of 3 million individuals passed on of COPD in 2012 representing 6% of all passing all-inclusive and will turn into the fourth driving reason for death in 2030 [1,2]. It is one of the most widely recognized infections in the world, with a lifetime hazard evaluated to be as high as 25%, and now similarly influences both men and women [3].

Chronic obstructive aspiratory illness (COPD) is a disorder portrayed by decreased maximum expiratory flow and moderately constrained purging of the lungs; which don't change particularly more than a while and is caused by an enhanced chronic inflammatory response in the airways and lungs to harmful particles or gases [1,4].

Emphysema (parenchymal tissue destruction) and chronic bronchitis are the two most basic conditions that add to COPD. These two conditions normally happen together and can shift in seriousness among people with COPD. Chronic bronchitis is an aggravation of the lining of the bronchial tubes, which convey air to and from the air sacs (alveoli) of the lungs. It's portrayed by everyday cough and mucus (sputum) production. Emphysema is a condition wherein the alveoli toward the end of the smallest air entries (bronchioles) of the lungs are annihilated because of introduction to tobacco smoke and other disturbing gases and particulate issue [5].

COPD is the main source of morbidity and mortality, with information supporting future expectations of it turning into the third driving reason for death, bringing about a considerable and expanding overall monetary and social weight fundamentally determined by disease intensifications and hospitalizations [6].

The most regular respiratory side effects incorporate dyspnea, cough as well as sputum creation. The pathology comprises of airway route mucosal aggravation and edema, along with hypertrophy of the loss of alveolar septa the most well-known respiratory indications incorporate dyspnea, hack, and additionally sputum creation. These side effects might be under-detailed by patients [1,7].

Chronic obstructive pulmonary disease (COPD) remains one of the most regular diseases around the world. The quantity of pharmacological drugs accessible to treat patients with COPD has expanded in the course of the last not many decades. The vast majority of the novel therapeutic agent results from the alteration of older compounds that are currently increasingly strong, last more, and are conveyed in better inward breath gadgets. Though various guidelines with respect to therapeutic calculations exist around the world, the most generally embraced approach is the one proposed by the Global Initiative in Chronic Obstructive Lung Disease (GOLD) in which the patients are separated by their announced dyspnea seriousness and their fuel history during the earlier year. In any case, the suggested characterization of COPD patients in A B C and D bunches as indicated by which helpful plans are picked isn't just mind boggling yet additionally doesn't appear to have any clinical value since it needs clear contrasts with respect to disease results. This is likely the explanation that the most recent GOLD suggestions propose a mind-boggling calculation of venturing here and there treatment as per the patient's qualities and treatment reaction [8].

The factors influencing COPD progression

COPD is a heterogeneous disease that varies from person to person with respect to lung pathology, natural history of disease, and comorbidities. Over the past four decades researchers has written several hypothesis or theories on the development of COPD: the British hypothesis stated that the presence of cough and sputum was the key factor in COPD, the Dutch hypothesis pointed to the presence of increased airways responsiveness, the Swedish hypothesis stressed on the part of genetic factors and the American hypothesis stated the development of emphysema is the main risk factor for the development of COPD [9-11].

Although, cigarette smoking is the notable COPD risk factor, but it is not the only hazard and there is predictable proof from epidemiologic studies that non-smokers are likely to develop airflow limitation. [Gold COPD] Other significant risk factors includes genetic factors, exposure to dust, vapor, fumes, sex and age, asthma, infections, poorer health status, severe airflow limitation, higher degree of emphysema, and an increased WBC count [12,13].

***Address for Correspondence:** Kalra M, School of Pharmaceutical Sciences, Apeejay Stya University, Sohna-Palwal Road, Gurgaon, Haryana-122103, India, Tel: +1 559-225-6100; E-mail: mohitkalra598@gmail.com*

Received 12 August, 2020; **Accepted** 26 August, 2020; **Published** 01 September, 2020

Genetic factors: The most popular hereditary factor connected to COPD is a deficiency $\alpha 1$ antitrypsin, a major circulating inhibitor of serine protease which arises in 1-3% of patients with COPD. The studies have proved that the parenteral lung function is related with the lung function of the offspring like the offspring's are likely to develop poor lung function if the parents has the lowest lung function. Conversely, the parents who have the highest lung function their offspring lung function develop properly. It is also possible that some genes lead to the development of airflow obstruction resulting in emphysema, whereas others contribute to chronic airway inflammation resulting in airway narrowing [14].

Although, it is uncertain that these genes are directly responsible for COPD or are just a marker of genes.

Age and gender: Lung function reaches to its peak level at young, begins to decrease in the third and fourth decade years of life. In spite of the fact that this decreased capacity is judged ordinary, a few scientists have announced that older individuals with elevated levels of lung work live longer than do those with low degrees of lung function. The role of gender in development of COPD is questionable and has been the subject of a lot of research. Historically, COPD are seen more frequent in men than in women, regarding patterns of smoking and occupational exposures. Studies has shown that, women are more susceptible to development of COPD than men when given equal exposures, but it still remains a topic of investigation. This notion demonstrated a greater burden of small airway disease in female in contrast to male with COPD despite a similar history of tobacco smoking [12,14].

Exposure to dust: Introduction to different tidies, synthetic compounds, fumes, and exhaust in the working environment is a factor for some individuals with COPD. One report demonstrated that 19.2% of COPD cases in the USA were owing to work exposures, with this extent being 31.1% in non-smokers. In nations of low income, where exposures to residue and exhaust could be greater than in high-pay countries due to less tough laws, work exposures can accept high significance as a risk factor.

Asthma: According to the Dutch hypothesis, asthma leads to development of COPD, although this topic remains controversial. Discoveries of cross-sectional examinations have shown a huge cover of up to 30% of people who have a clinical diagnosis of COPD and asthma. In a report from a longitudinal cohort of the TUCSON EPIDEMIOLOGICAL AIRWAY OBSTRUCTIVE DISEASE, adults with asthma were found to have 12-fold higher risk of acquiring COPD over time compare to those with asthma. Asthma patient develop irreversible airflow limitation along with excess loss of FEV1 [12,14].

Smoking: Around the world, tobacco smoke remains the most significant reason for COPD. WHO evaluates that in high-salary nations, 73% of COPD mortality is identified with smoking, with 40% identified with smoking in countries of low income pay. This connection is influenced exceptionally by qualities, on the grounds that not all smokers proceed to create COPD. Lately, higher proportion of smokers as much as 50% have been noted to develop COPD. Moreover, smoking during pregnancy can contrarily influence fetal lung development and result in the improvement of lung disease. Smoking of cannabis has been connected to respiratory indications however not decisively to advancement of COPD.

Socioeconomic and related factors: There is a strong evidence that risk of COPD development id not proportional to socioeconomic status. Population with low income pay in general are at higher danger of developing COPD and its complexities than the population with higher income. Poor economic status is a measure for many factors that increase the risk of COPD like, poor healthful status, swarming, introduction to poisons including high work exposures and high smoking rates (in nations of low and center salary), poor access to medicinal services, and early respiratory contaminations.

Infections: Infections have a significant role in both development and progression of COPD. If a patient has a history of severe childhood respiratory infection than they are likely to associate with reduce lung function and elevated respiratory inflammation. Infection is the main cause of exacerbation in COPD. Most of the COPD exacerbation are associated to bacterial and viral infection [12,14].

Non-pharmacological treatment for COPD

Rehabilitation: Patients with COPD exhibit reduced degrees of unconstrained physical activity in contrast to healthy controls. Rehabilitation includes physical activity, education and psychological support aimed at reducing disability and improving patient participation. It addresses exercise deconditioning, social isolation, altered mood states, such as anxiety and depression, muscle wasting and weight loss. It has been demonstrated that activity limit is a free factor decidedly affecting hospital readmission; in any case, rehabilitation has not been exhibited to improve patient survival.

In any case, the patients who can profit the most from rehabilitation has demonstrated the best endurance rates after some time. It has improved the outcomes in patients, both with and without chronic respiratory failure. Exercise training sessions range in frequency from daily to weekly. Each session lasts up to 10-45 minutes. The minimal range of the rehabilitation program should not be less than 10-12 however, the longer the program, the higher the efficacy. Additionally, COPD patients in the ICU benefits from rehabilitation. Patients with very impaired condition, received a long-term ventilation thus they responded to whole-body and respiratory muscle training in terms of improving strength, weaning outcome and functional status [15,16].

Smoking cessation: Smoking cessation is the best and most significant early mediation accessible in the administration of COPD. Smoking adds to the advancement of COPD by expanding the annual rate of decrease in force expiratory volume in 1 second (FEV1) from a population in an average of around 25 ml/year in non-smokers to an average of 40 ml/year in smokers. The cessation support offered to every individual smoker must be custom fitted to singular needs, however with acknowledgment that, when all is said in done, the more serious the help acknowledged and given, the more the possibility of achievement. The fundamental segments of successful smoking cessation includes basic counsel, thought of self-improvement materials, individual and gathering conduct support, nicotine substitution treatment (NRT), and bupropion (a non-traditional pharmacological treatment for COPD patients). Advising and conduct treatments for smoking cessation expect to inspire the smoker to stop and create skills andtechniques to adapt to nicotine withdrawal, or the pressure to smoke. Depending upon the degree of help acknowledged by the smoker, these medications can increment the suspension achievement rate to about 7%. NRT improves the suspension achievement rates accomplished by these mediations by roughly 70%; it is accessible in several formulations, including transdermal patches, gum, inhalers, and nasal splash. Bupropion is an antidepressant that is moreover a successful smoking cessation treatment, early involvement in bupropion is as effective as NRT [16-18].

Long-term oxygen therapy (LTOT): LTOT is one of the main treatments for patients with advanced COPD. The primary goal of LTOT is to increase the baseline arterial oxygen tension PaO2 at least60 mmHg at rest along with preserving vital organ function by ensuring sufficient oxygen supply. It can be administered continuously mainly during exercise to relieve dyspnea.

LTOT administered continuously for more than 15 hours a day to COPD patients with chronic respiratory failure has been shown to increase survival in the patients by improving the patient's physiological parameters i.e., exercise capacity, lung mechanics, and mental state. According to GOLD, LTOT is introduced in the stage 3 which is a severe stage. The prescription for LTOT should always include the source of supplemental oxygen whether in gas or liquid state, method of delivery, duration of use, and flow rate at rest, during exercise and sleep. Oxygen therapy given during exercise in patients is known to produce significant short term benefits, such as improvement of exercise endurance and dyspnea.

Once placed on LTOT the patents are asked for re-evaluation after 60 to 90 days to determine if oxygen is therapeutic and still response as indicated or not.

Surgery: Bullectomy is an older surgical procedure established for bullous emphysema. Removal of large bulla that does not contribute to gas exchange, the adjacent lung parenchyma is decompressed. Some investigators have recommended that the bulla must occupy 50% of the hemithorax and produce displacement of the adjacent lung.

Lung volume reduction surgery (LVRS) is a surgical procedure in which parts of the lung are dissected, to reduce hyperinflation, making respiratory muscles more effective by improving their mechanical efficiency and improving overall gas exchange. Successful LVRS results in the improvement in lung function, exercise capacity and long-term quality of life in patients with COPD. The best candidate for LVRS is a COPD patient with severe airflow limitation (FEV<35% pred.), hyperinflation with emphysema, without relevant carbon dioxide retention and low exercise capacity.

Lung transplantation is an optional for limited number of patients, with highly impaired lung function, hypercapnia and secondary pulmonary hypertension. A COPD patient may be considered for transplantation when FEV1< 25% and arterial carbon dioxide tension PaCO2 less than 55 mmHg.

According to the declaration by International Society for Heart and Lung Transplantation's registry, survival for emphysema is 85.7% at 1 year and 68.3% at 3 years [19-21].

Non-invasive positive potential ventilation (NPPV): NPPV is delivered via nasal or face mask, to avoid the risks associated with invasive ventilation. It aids in ventilation by improving inspiratory flow rate, correcting hypoventilation, resting respiratory muscles and resetting the central respiratory drive.

Short-term trials in hypercapnic COPD patients have shown that NPPV plus LTOT is able to significantly improve sleep quality and daytime gas exchange as well as to reduce ICU admissions in contrast to LTOT alone. COPD patients receiving nocturnal NPPV showed a lower PaCO2 level over time as compared with the LTOT group. NPPV can be successfully used carefully in selected COPD patients based on their history and functional severity, showing nocturnal hypoventilation and relevant daytime hypercapnia [16].

Medications used for COPD

Pharmacologic treatment for COPD is utilized to lessen indications, diminish the recurrence and seriousness of intensifications, and improve practice resilience and wellbeing status.

Bronchodilators: Bronchodilators are medications that are involved in the increment of FEV1 and/or change other spirometry variables. It aids in adjusting airway smooth muscle tone rather and widening of airways rather than changes in lung elastic recoil. They render reduction of dynamic hyperinflation at rest during exercise and improve exercise execution.

Utilization of short acting bronchodilators on a regular basis is not generally recommended.

Beta2-agonists: Beta2-agonists aids in relaxing airway smooth muscle by stimulating beta2- adrenergic receptors, which increases cyclic AMP and produces functional antagonism to bronchoconstriction. There are short-acting (SABA) and long-acting (LABA) beta2-agonists. SABA has short duration of action, and tends to wear off in 4 to 6 hrs. LABAs shows duration of action of 12 or more hours. Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV1 and lung volumes, dyspnea, health status, exacerbation rate and number of hospitalizations, but have no effect on mortality or rate of decline of lung function.

Indacaterol is a once daily LABA that improves breathlessness, health status and exacerbation rate. Oladaterol and vilanterol are additional once daily LABAs that improve lung function and symptoms.

Older patients treated with higher doses of beta2-agonists, may not respond effectively, regardless of route of administration. Nonetheless, hypokalemia can occur if combined with thiazide diuretic and oxygen consumption elevates under resting condition in patient with chronic heart failure [22,23].

Antimuscarinic drugs: Antimuscarinic drugs hinders the Bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle. Short-acting antimuscarinics (SAMAs), like ipratropium and oxitropium acts by blocking inhibitory neuronal receptor M2 (cause vasoconstriction) and long-acting antimuscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide and umeclidinium have prolonged binding to M3, thus prolonging the duration of bronchodilator effect [24,25].

Methylxanthines: Theophylline is the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases whose clearance declines with age. Addition of theophylline to salmeterol aids in greater improvement in FEV1 and breathlessness than salmeterol alone. Toxicity is dose-related, which is a main problem with xanthine derivatives because they have low therapeutic ratio and most benefit occurs only near-toxic dose [26-28].

Combination bronchodilator therapy: Two bronchodilators with different mechanism of action increases the degree of bronchodilation with a lower risk of side-in contrast to single bronchodilator. Combinations both the bronchodilators LABA and LAMA are superior compared to either medication alone in improving FEV1 and symptoms. There are numerous combinations of a LABA and LAMA available now in a single inhaler [29,30].

Inhaled corticosteroids (ICS): Studies has shown that regular treatment with ICS alone do not modify the long term decline of FEV1 nor mortality in patient with COPD. According to TORCH trial, a trend toward higher mortality was observed for patient treated with fluticasone propionate alone compared to those receiving placebo or salmeterol plus fluticasone propionate combination [31].

In patients with moderate to very severe COPD and exacerbations, combination of ICS and LABA is more effective than either component alone in improving lung function, health status and reducing exacerbations [32].

Triple inhaled therapy: Triple therapy is a treatment which involves the combination of LABA plus LAMA plus ICS. According to COPD triple therapy issued during severe COPD i.e., Stage IV. Triple therapy may improve lung function and patient reported outcomes. Adding a LAMA to existing LABA/ICS improves lung function and patient reported outcomes, in particular exacerbation risk. Although, RCT did not demonstrate any benefit of adding ICS to LABA plus LAMA on exacerbations. More evidence is required to draw conclusions on the benefits of triple therapy LABA/LAMA/ICS compared to LABA/LAMA [33].

Oral glucocorticoids: Oral glucocorticoids tends to have numerous side effects, including steroid myopathy contributing to muscle weakness, decreased functionality, and respiratory failure in very severe COPD [34]. Though oral glucocorticoids helps in management of exacerbations, they have no role in the chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.

Assessment of COPD patients

Currently, the Global Initiative for COPD (GOLD) promotes the "ABCD" assessment of COPD patients based on symptoms severity (assessed by questionnaire) and exacerbation risk (low risk consisting of no more than one moderate-severer exacerbation during the past year).

- GOLD group A includes patients with low symptom severity and low exacerbation risk.
- GOLD group B includes patients with high symptom severity and low exacerbation risk.
- GOLD group C includes patients with low symptom severity but high exacerbation risk.
- GOLD group D includes patients presenting high symptom severity and high exacerbation risk (Global initiative for Chronic Obstructive Lung disease (GOLD) [35].

Classification of severity of air limitation (derived from the GOLD guidelines)

GOLD guidelines have classified the severity of COPD as mild, moderate, severe, or very severe, based on the patient's symptoms, and lung function as assessed by measurement of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) and its ratio (FEV1/FVC).

FEV1 is the amount of air you can force from your lungs in one second. Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled [36]. Spirometry is the fundamental diagnostic method because it is easy and inexpensive to perform, and thus it can be used as a screening test [37]. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator to minimize variability (Table 1).

Chronic cough and sputum production should often be taken into consideration as it may precede the development of airflow limitations and favor the cause of COPD. However, not all individuals with cough and sputum production will go on to develop COPD. The seriousness of COPD will determine the therapy required [37].

Pharmacologic therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. Bronchodilator plays a central role in its treatment and is mainly provided in order to reduce or prevent symptoms. The Global Initiative for Chronic Obstructive Lung Disease 2015 rules and other worldwide rules shed light on three primary classes of prescriptions regularly utilized in treating COPD referred to as bronchodilators, corticosteroids, and methylxanthines. Breathed in therapy is more preferred also, long-acting specialists are advantageous and more compelling than short-acting ones. A stepwise methodology is frequently implemented beginning with short-acting bronchodilators on a "case by case" basis because of their rapid onset of action, then fusing long-acting bronchodilators as the backbone of support treatment, and in the long run, fusing corticosteroids as persistent side effects and disease seriousness progress [7].

Recently, single inhalers containing an inhaled glucocorticoid, a LABA, and a LAMA have been developed; these inhalers offer potential advantages in practicality and adherence to treatment [38].

Dual dose therapy used in COPD

For some years, doctors have consolidated (combine) medications by prescribing various inhalers for advance clinical effectiveness, it has not been much time that preliminaries have demonstrated this is as effective as giving similar treatment in a single inhaler [39]. Nonetheless, when referring to the dual combination treatment with bronchodilators, we allude both drugs with a different mechanism of action and duration of action which elevates the span of bronchodilation with a lower risk of side-effects, in contrast to increasing dose of single bronchodilator. There are abundant combinations of a LABA and LAMA in a single inhaler available that are currently licensed for use in COPD [39,40]. A lower dose of LABA/LAMA twice-a-day has additionally shown improvement in symptoms and health status in COPD patients [41].

Currently, the LAMA/LABA combination in single inhaler device disposable on the market include [35]:

A. Umeclidinium/ Vilanterol (Anoro R),

B. Tiotropium/Olodaterol (Stiolto R),

C. Glycopyrrolate/Formoterol (Bevespi R)

D. Glycopyrronium/ Indacaterol (Ultibron R) available in the United States.

E. Glycopyrronium/Indacaterol (Ultibro R),

F. Tiotropium bromide/ Olodaterol (Spiolto R),

G. Umeclidinium/Vilanterol (Anoro R),

H. Aclidinium/Formoterol (Duaklir R Genuair R , Brimica R Genuair R) are available in the European Union

Pharmacology mechanism of action of LAMA/LABA fixed dose combination for COPD

Long-acting beta-agonist and LAMA are two significant classes of bronchodilators and presently the chief prescriptions for patients with COPD. [42]

LABA relax airway smooth muscle and cause bronchodilation by linking with beta2-adrenergic receptors located on airway smooth muscle with consequent activation of a stimulatory M3 (guanosinethreephosphate- (GTP) binding protein). It mediates intracellular adenyl cyclase stimulation, with a consequent increase in cyclic adenosine monophosphate levels, leading to a reduction in smooth muscle airway contractility. This relaxation is also caused by activation of large-conductance Ca2+ activated K+ channels via G2 which leads to plasma membrane hyperpolarization. [6,42].

Long-acting beta-agonist can be divided into once-daily and twice-daily LABA. Once-daily LABA is indacaterol (IND), olodaterol (OLO), and vilanterol (VIL). Twice-daily LABAs are formoterol fumarate (FF) or propionate (FP) and salmeterol (SAL). [43].

LAMA block the bronchoconstriction effect of acetylcholine on M3 (regulates intracellular calcium concentration and calcium-modulated proteins) muscarinic receptors, they have prolonged binding to M3 muscarinic receptors with faster dissociation from M2 muscarinic receptors. Long-acting muscarinic competitively and reversibly antagonizes M3 receptors, resulting in the relaxation of bronchial smooth muscle. LAMA antagonists such as tiotropium (TIO), umeclidinium (UMEC), and glycopyrronium (GLY), while aclidinium (ACL) is dosed twice a day. [44,45].

Bronchodilator monotherapy is not always satisfactory for patients with advanced COPD. In that situation, a dual-bronchodilator therapy consisting of LAMA and LABA is a good option. LAMA/LABA fixed-dose combinations (FDCs) have been shown to improve lung function, lung hyperinflation, exercise capacity, quality of life, and exacerbation frequency thereby slowing disease progression in COPD.19 These combinations have a synergistic effect rather than just being additive one. [46]

There is developing findings and proof proposing that combining a fixed portion of a β2 - agonist and a muscarinic antagonist accomplish better bronchodilation and clinical results compared with either operator alone. This combination gives an effective, convenient, conceivably more secure option in contrast to LABA/ICS combination.

Materials and Methods

Several comparisons were made under different studies by different

Table 1. Classification of severity of COPD [1,11].

Stages	Characteristics	Comments
Mild COPD	· Chronic symptoms (cough, sputum production) · FEV1/FVC < 70% · FEV1 80% predicted	Cough and sputum production proceeds along with airflow limitation by many years. At this stage, the patient may be unaware regarding their abnormal lung function.
Moderate COPD	· With or without chronic symptoms (cough, sputum production) · FEV1/FVC < 70% · 50% FEV1 < 80% predicted	Symptoms gradually progress at this stage, with uneasiness and shortness of breath typically developing on forceful effort.
Severe COPD	· With or without chronic symptoms (cough, sputum production) · FEV1/FVC < 70% · 30% ≤ FEV1 < 50% predicted	Emphysema is typically seen at this stage which limits the physical activities and exacerbation develops at the beginning of this stage.
Very severe COPD	· With or without chronic symptoms (cough, sputum production) · FEV1 ≤ 30% predicted	Exacerbations may be life-threatening.

researchers to review the efficacy and safety of a combination of bronchodilators LABA/LAMA in soothing the exacerbations in COPD (Figure 1).

The figure shows a comparison of the effect of different combinations of long-acting beta-agonists and muscarinic antagonists on trough forced expiratory volume in 1 s (FEV1) where we can observe TIO and OLO monotherapy produces a similar but less effective response, on the other hand, TIO and OLO combination in the same proportion is very effective in contrast to TIO and OLO combination in different proportion.

Multiple randomized, double-blind, preliminaries were conducted of these combinations [23].

The first study was tiotropium versus olodaterol (10,000 patients), the second ipratropium versus salbutamol (20 patients) [47].

In the first case, the dosage of TIO/OLO was given at the ratio of 5/5 and 2.5/5 OD, these bronchodilators not only improve pulmonary function than placebo but also result in significant improvement on dyspnea, exercise endurance. As stated in the studies TIO monotherapy 5and OLO 5 turns out to be less efficient in terms of pulmonary function {FEV, AUC 0-24, FEV AUC 0-12, FEV AUC12-24} and reducing symptoms of dyspnea in contrast to TIO/OLO 5/5.

In the second case, the study has shown that nebulized ipratropium (0.5 mg) and salbutamol (5 mg) monotherapy produced a similar onset of action and magnitude of bronchodilator response [24]. 20 patients were chosen, and among those 20 patients all had smoked for many years and fulfilled the criteria for chronic bronchitis. The mean forced expired volume in 1 second (FEV1) was 0.91, 1 (+ 0.36), mean vital capacity (VC) 2.73, 1 (+ 0.78). The test solutions were given and comprised: A normal saline 3 ml, salbutamol 5 mg (1.0 ml of 0.5% solution) and normal saline 2 ml, ipratropium bromide 0.5 mg (2 ml of 0.025% solution) and normal saline 1 ml and salbutamol 5 mg and ipratropium 0.5 mg solutions were administered. The FEV1 and FVC were measured on a dry spirometer and the best of three readings were selected. As a result, there was no statistical significance contrasts between the FEV1 response of ipratropium and salbutamol alone whenever during the investigation. Ipratropium and salbutamol in combination had statistically significant increases in FEV1 in contrast to salbutamol ($P < 0.05$) at all times and ipratropium for all times up to 4 h ($P < 0.05$). Vital Capacity for ipratropium alone became significantly greater than for salbutamol alone at 270 and 300 min ($P < 0.05$). Ipratropium and salbutamol singly produced similar peak FEV1 responses.

Triple dose therapy used in COPD

According to the studies undergone, the trial for once-daily single inhaler triple therapy i.e., fluticasone furoate, umeclidinium, and vilanterol leads to a significant decrease in the rate of moderate or severe COPD exacerbation and resulted in a better lung function in contrast to the dual therapy with fluticasone furoate-vilanterol or the dual bronchodilator umeclidinium-vilanterol for the patients having symptomatic COPD and exacerbation which are observed on the blood eosinophil levels on randomization [10].



Figure 1. Comparison the effect of different combinations of long-acting beta-agonists and muscarinic antagonists on trough forced expiratory volume in 1 s (FEV1).

The restricted proof is accessible for an impact of triple treatment on intensifications and as far as anyone is concerned this is the main long haul study to contrast a fixed triple and a long-acting muscarinic adversary [47].

Studies have for the most part been of the brief span and have for the most part not explicitly enrolled COPD patients in danger of fuel occasions. In one of only a handful of scarcely any drawn-out examinations, Aaron and colleague (d)s assessed compounding rates with long-acting muscarinic adversary alone or in the combination with either long-acting β_2-agonist or breathed in corticosteroids in addition to long-acting β_2-agonist for 52 weeks [48].

Development in the administration of COPD is the accessibility of blend inhalers containing a long-acting β_2-agonist and a long-acting muscarinic foe. Such bronchodilator blend inhalers have a job in the administration of COPD-particularly in light of the fact that the Flame study [49] recommended that contrasted and a breathed in corticosteroid/long-acting β_2-agonist mix, a long-acting muscarinic opponent/long-acting β_2-agonist blend diminished the pace of COPD intensifications and improved both lung capacity and wellbeing related nature of life. Neither our examination nor TRILOGY [50] can legitimately reply to the subject of the benefit of including a breathed in corticosteroid to a long-acting β_2-agonist in addition to long-acting muscarinic adversary mix. Moreover, the expansion of breathed in corticosteroids to support treatment with the blend of two long-acting bronchodilators isn't the most widely recognized triple therapy [51].

Triple breathed in treatment for COPD may be a viable pharmacological technique in chosen COPD phenotypes, including ACOS, eosinophilic, and 'visit exacerbator' phenotype [52], especially of serious degree, in which maximal bronchodilatation is required. Post hoc investigations of single focus controlled examinations show more noteworthy adequacy of corticosteroids in patients with ACOS [53], mainly characterized based on clinical utilitarian rules (history of asthma, a positive reversibility test to bronchodilators) and cell models (sputum eosinophilia) [54], a phenotype that speaks to about 20% of the entire COPD populace [1]. The particular viability of fluticasone furoate/vilanterol FDC, as far as fuel rate decrease, in COPD patients with raised fringe blood eosinophils rather than those with typical blood eosinophils, as appeared by a review information examination [32] from a Phase III urgent investigation [55], further backings the significance of a phenotype-based way to deal with pharmacological treatment of COPD [56], which may likewise explain the remedial job of ICS, and ICS/LABA/LAMA FDC, in this disease.

A developing assemblage of proof recommends that triple treatment with LABAs, LAMAs, and ICS is strong in patients with increasingly serious COPD, for example, those with visit intensifications. This makes triple treatment an alluring blend in COPD. Hence, an assortment of triple mixes is right now being worked on [57].

There is presently more proof that there are subsets of patients (basically, visit exacerbators with overwhelming ceaseless bronchitis and those with cover between COPD furthermore, asthma) with an ideal reaction to treatment with ICSs [58], triple treatment ought to be considered at any rate in the gathering of patients with increasingly serious COPD who are visit exacerbators, and furthermore to treat patients with asthma COPD cover disorder to oversee both the COPD and asthma segments of the illness. Strikingly, enhancements in lung capacity can likewise be accomplished through joining triple treatment with aspiratory recovery in patients with progressed COPD [59].

Regardless, we emphatically accept that the improvement of bifunctional drugs, atoms explicitly intended to have two unmistakable essential pharmacological activities dependent on particular pharmacophores, may fill in as a reason for improved triple-treatment fixed-portion blend inhalers through coformulation that could convey three correlative remedial impacts for patients with COPD utilizing just two medications what's more, along these lines, possibly accomplish preferable viability over is evident with the present blend items that command the treatment of COPD [56].

Patients with COPD not to treat with triple treatment

1) All examinations performed, until now with triple treatment has included

symptomatic patients, i.e., patients with either CAT ≥ 10 as well as adjusted Medical Research Council ≥ 2. We see no explanation with the proof accessible now to think about triple treatment for asymptomatic patients, except if the patient satisfies point 2, 3 or 4 plots in the past area and has hardly any manifestations in the middle of intensifications.

2) Similarly, regardless of whether symptomatic smokers with ordinary lung work or prohibitive debilitation may in actuality have a comparable danger of intensifications as symptomatic smokers with obstructive impedance [60], we see no explanation with the proof accessible now to think about triple treatment for symptomatic patients without wind stream constraint.

3) While the ongoing examinations with triple treatment in a solitary inhaler propose an impact on endurance following 1 year of treatment [61], this impact was watched distinctly on a moderate to extreme populace of symptomatic patients in danger of intensifications, and endurance was not a predefined result Thus, until an appropriately planned investigation is performed and is certain on this result, triple treatment ought not be considered to improve endurance in COPD patients.

4) The latest triple treatment study included symptomatic COPD patients with moderate-to extreme wind current constraint without a past filled with intensifications in the earlier year, had a span of a half year and was controlled on lung work and no patient-related result (PRO) (for example, worsening) [62]. Despite the fact that the investigation indicated predominance of triple over double blends on lung work as well as on applicable optional PROs (for example, side effects and intensifications), without security concerns, we for the most part need in any event two reliable RCTs on a clinically applicable essential result before giving proposals. Along these lines, we accept that triple treatment ought not to be suggested as normal treatment for patients without a past filled with intensifications in the earlier year.

5) COPD and eosinopenia. There is proof to propose that the impact of ICS on COPD intensifications increments with the quantity of circling eosinophils, and that they are ineffectual in patients with low blood eosinophils (50-100 cells, μL-1), and that eosinopenia expands the danger of pneumonia [63]. Thus, except if carefully fundamental on the grounds that either bronchodilators are not adequate, or there is a background marked by dynamic serious uncontrolled asthma, we would not suggest the utilization of ICS, including triple treatment, in patients with <100 eosinophils, μL-1.

6) Patients with COPD are at expanded danger of contaminations, especially pneumonia, bronchiectasis, tuberculosis, and even non-tuberculous mycobacterial diseases [64]. Patients with COPD in danger of intermittent pneumonias with or without bronchiectasis, patients with bronchiectasis and repetitive respiratory diseases, and patients with dynamic tuberculosis ought to be not be treated with ICS, including triple treatment, and if ICS are carefully required, they ought to be deliberately observed for the danger of contamination.

7) Patients with HIV treated with antiretroviral treatment (ARVs) frequently present with COPD, which is now and again serious. ICS ought not to be co-directed in HIV patients on an ARV-supported routine because of the solid hindrance of their digestion, which builds the danger of Cushing's disorder, especially fluticasone and budesonide. Just beclomethasone dipropionate might be thought of, if carefully required, yet with cautious checking of medication measurement or timing of organization [65].

8) Similarly, in clinical practice, we ought to be cautious in thinking about the individual or combined bronchodilator segments (LABA and additionally LAMA) or triple treatment in extreme multimorbid COPD patients (especially serious arrhythmias, extreme cardiovascular breakdown as well as ischemic coronary illness, stroke, transient ischemic assaults, and so on.) in whom the viability/wellbeing of these specialists have not been tried [66].

Results and Discussion

The ongoing updates to the GOLD rules underscore mix bronchodilator treatment and LAMA/LABA FDC medications are probably going to turn into the backbone of medicines for some patients with symptomatic COPD. These treatments are all around endured and safe. They have been appeared to unassumingly decrease aviation route deterrent in examination with bronchodilator single dose therapy. They diminish intensifications in any event just as LABA/ICS treatment without the additional dangers related with ICS. They additionally show up to improve PROs, for example, dyspnea and QoL, however these upgrades appear to be less vigorous at whatever point estimated as mean changes in huge preliminaries. A few patients will have increasingly significant clinical reactions to these treatments than others. It is significant that the desires for both doctor and patient are steady with the range and level of clinical upgrades exhibited in clinical preliminaries. Rules give priceless help to doctors looking for the correct treatments for their patients. Eventually, there are numerous contemplations that impact treatment determination. Doctors will need to take tolerant explicit indications, physiology, intensification seriousness and recurrence, and nearness of coinciding conclusions into account. Oftentimes, inhaler accessibility and cost will impact treatment determination. Deciding the correct treatment for a singular patient despite everything requires cautious thought to these components, close follow-up to decide physiologic and symptomatic reaction, and an eagerness to modify or change treatment dependent on reaction.

Triple treatment ought not be applied to most patients determined to have COPD as the dominant part have low indications and low intensification chance [67] and can be controlled with non-pharmacological intercessions furthermore, bronchodilators just (Figure 1). Be that as it may, the individuals who stay symptomatic in any event, during support treatment with bronchodilators or had a moderate-to-serious compounding in the earlier year, persevering quickened decrease in lung work or those having a past analysis of asthma or covering qualities with asthma, may as we would like to think be contender for in any event a preliminary with triple treatment, despite the fact that this isn't consistent with GOLD, EMA or FDA suggestions. On the other hand, triple treatment ought not be considered in asymptomatic subjects paying little heed to the level of wind current impediment, in subjects without a right determination, or in subjects at high danger of inconveniences connected to its segments, especially the ICS. We understand that a portion of our recommendations get from clinical practice and are not upheld by proof, also, in this way that the impacts not out of the ordinary are obscure and may be negated by future examinations. Be that as it may, as regularly occurs in medication, we trust that our recommendations may be of some assistance for singular patients who don't meet the models suggested by the present reports.

Triple dose therapy with single inhaler is found much for efficient and efficacious to reduce the exacerbations and severity of Chronic Obstructive Pulmonary Syndrome.

Different studies, researches, preliminaries and surveys with experimental data clearly shows the potential of triple dose single inhaler in comparison to those of dual dose and single dose.

In a trial study performed, once-every day single-inhaler triple treatment with fluticasone furoate, umeclidinium, what's more, vilanterol brought about a fundamentally lower pace of moderate or serious COPD intensifications furthermore, better lung capacity and wellbeing related personal satisfaction than double treatment with fluticasone furoate-vilanterol or the double bronchodilator umeclidinium-vilanterol among patients with symptomatic COPD and a background marked by intensifications. These advantages were watched in any case of the patients' blood eosinophil levels at randomization (Figure 2).



Figure 2. Comparison between model-estimated rate and time-to-first-event analysis.

Conclusion

As it can be clearly seen from the above graphical representation, furthermore, all the studies and proofs for the efficacy of triple dose with respect to dual and single are mentioned in triology, trinity, and tribute studies which are registered at ClinicalTrials.gov as NCT01917331, NCT01911364 and NCT02579850, respectively.

References

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. *GOLD* (2018).
2. Erika, Zavaglia, Kabbach Adriana, Mazzuco Audrey and Borghi-Silva Ramona, et al. "Increased parasympathetic cardiac modulation in patients with acute exacerbation of COPD: how should we interpret." *Int J COPD* 12 (2017):2221-2230.
3. Barnes, Peter. "New anti-inflammatory targets for chronic obstructive pulmonary disease New anti-inflammatory targets for chronic obstructive pulmonary disease." *Nat Rev Drug Discov* 12 (2013):543-559.
4. American Thoracic Society. "Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma." *Am Rev Respir Dis* 136 (1987): 225-244.
5. Mayo clinic. "Mayo Foundation for Medical Education and Research." *MFMER* (1998-2020).
6. Wijdan, Ramadan, Wissam Kabbara, Ghada Khoury and Sarah Assir. "Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease." *Int J COPD* 10 (2015): 2347-2356.
7. Nicholas, Gross, Donald Tashkin, Randall Miller and Joseph Orenc, et al. "Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group." Respiration 65 (1998): 354-362.
8. Green, Hillas, Amair Papaporfyriou, Khoury Dimakou and Aney Papaioannou. "Pharmacological treatment of stable COPD: need for a simplified approach Pharmacological treatment of stable COPD: need for a simplified approach." *Postgrad Med* 132 (2020): 126-131.
9. Anthonisen, Nair. "The British hypothesis revisited." *Eur Respir J* 23 (2004): 657-658.
10. Vestbo, Jain and Prescott East. "Update on the "Dutch hypothesis" for chronic respiratory disease." *Thorax* 53 (1998): 15-19.
11. Stoller, James and Aboussouan Lucy. "α1-antitrypsindeficiency." *Lancet* 365 (2005): 2225-2236.
12. David, Mannino and Sonia Buist. "Global burden of COPD: risk factors, prevalence, and future." *Lancet* 370 (2007): 765-773.
13. Cohort, Mullerova and Diego James. "Hospitalized Exacerbations of COPD Risk Factors and Outcomes in the ECLIPSE cohort." *Chest* 147 (2015): 999-1007.
14. Ladinajoosa , Peter and Parea Andrew. "SWISS MED WKLY Genetic risk factors for chronic obstructive pulmonary disease." *Sandfordb* 132 (2002): 27-37.
15. Enrico, Clini and Nair Ambrosin. "No pharmacological treatment and relief of symptoms in COPD." *Eur Respir J* 32 (2008): 218-228.
16. Enrico, Clini, Stefania Costi, Silvano Lodi and Giuseppina Rossi. "Non-pharmacological treatment for chronic obstructive pulmonary disease." *Med Sci Monit* 9 (2003): 300-305.
17. Anderson, Erick, Jorenby Dous and Scott Wrick. "Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation." *Chest* 121 (2002): 932-941.
18. Silagy, Criss, Mant Denny and Fowler Greek. "Nicotine replacement therapy for smoking cessation." *Cochrane Database Syst Rev* 6 (2000): 146.
19. Mitrouska, Luis, Tzanakis Neer and Siafakas Michal. "Oxygen therapy in chronic obstructive pulmonary disease. In: Siafakas NM, ed. Management of Chronic Obstructive Pulmonary Disease". *Eur Respir Mon* 38 (2006): 302-312.
20. Tarpy, Stefen and Celli Brown. "Long-term oxygen therapy." *N Engl J Med* 333 (1995): 710-714.
21. Musko, Siafakas, Peter Vermeire, Brav Pride and Pluto Paoletti. "The European Respiratory Society Task Force. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)." *Eur Respir J*, 1995; 8: 1398-1420.
22. Geake, Jame, Dabscheck Eleme, Wood-Baker Rock and Cates Crick. "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta (2)-agonists or placebo for chronic obstructive pulmonary disease." *Cochrane Database Syst Rev* 1 (2015): CD010139.
23. Koch, Aurus, Pizzichini Emer and Hamilton Amith. "Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat (R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies." *Int J Chron Obstruct Pulmon Dis* 9 (2014): 697-714.
24. Melani Smith. "Long-acting muscarinic antagonists." *Expert Rev Clin Pharmacol* 8 (2015): 479-501.
25. Appleton, Smith, Jones Tale and Poole Paul. "Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease." *Cochrane Database Syst Rev* 3 (2006): 6101.

26. Ram, Fin, Jones Paul and Castro Awis. "Oral theophylline for chronic obstructive pulmonary disease." *Cochrane Database Syst Rev* 4 (2002): 3902.
27. McKay, Smith, Howie Criws, Thomson Amer and Whiting Bit, et al. "Value of theophylline treatment in patients handicapped by chronic obstructive lung disease." *Thorax* 48 (19930: 227-232.
28. Cosio, Grew, Shafiek Hall and Iglesias Austin. "Oral Low-dose Theophylline on Top of Inhaled Fluticasone Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial." *Chest* 150 (2016): 123-130.
29. Cazzola, Mick and Molimard Maul. "The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD." *Pulm Pharmacol Ther* 23 (2010): 257-267.
30. Mahler, Dan, Kerwin Edwick and Ayers Tail. "FLIGHT 1 and FLIGHT 2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease." *Am J Respir Crit Care Med* 192 (2015): 1068-1079.
31. Nannini, Louis, Lasserson Jame and Poole Paul. "Combined corticosteroid and long-acting beta (2)-agonist in one inhaler versus long-acting beta (2)-agonists for chronic obstructive pulmonary disease." *Cochrane Database Syst Rev* 9 (2012): 6829.
32. Nadeem, Jame, Taylor Smith and Eldridge Mick. "Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review and comment on trial methodology." *Respir Res* 12 (2011): 107.
33. Brusselle, Grew, Price Din and Gruffydd Jones. "The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK." *Int J Chron Obstruct Pulmon Dis* 10 (2015): 2207-2217.
34. Manson, Saul, Brown Red, Cerulli Austin and Vidaurre Cris. "The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use." *Respir Med* 103 (2009): 975-994.
35. Mario, Malerba and Valentina Foci. "Single Inhaler LABA/LAMA for COPD." *Front Pharmacol* 10 (2019): 390.
36. Erica, Cirino. "FEV1 and COPD: How to Interpret Your Results." *Healthline* 1 (2017): 108.
37. Tomasz, Golczewski, Wojciech Lubinski, Andrzej Chciałowski and Golczewski tony, et al. "A mathematical reason for FEV1/FVC dependence on age." *Respiratory Res* 13 (2012): 57.
38. David, Bellamya, Jacques Bouchard, Svein Henrichsenc , Gunnar Johanssond, et al. "Guidelines: Management of Chronic Obstructive Pulmonary Disease (COPD)." *Int Primary Care Respiratory Group* (2011).
39. Austin, Lipson, Frank Barnhart, Noushin Brealey and Jean Brooks, et al. "Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD." *Engl J Med* 378 (2018): 1671-1680.
40. Cazzola, Mike and Molimard Mors. "The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD." *Pulm Pharmacol Ther* 23 (2010): 257-267.
41. Bens, Vlies. "A rational approach to single, dual and triple therapy in COPD." *Respirology* 21 (2016): 581-589.
42. Mahler, Dawis, Kerwin Emen and Ayers Tin. "FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease." *Am J Respir Crit Care Med* 192 (2015): 1068-1079.
43. Montuschi, Paul, Malerba Mike, Macis Gim and Mores Noel, et al. "Triple inhaled therapy for chronic obstructive pulmonary disease." *Drug Discov* 21 (2016): 1820-1827.
44. Horita, Nair, Goto Amith, Shibata Yemen and Ota Emic, et al. "Long-acting muscarinic antagonist (LAMA) plus long-acting betaagonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)." *Cochrane Database Syst Rev* 2 (2017): 12066.
45. Pera, Tin and Penn Brown. "Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway." *Curr Opin Pharmacol* 16 (2014): 72-81.
46. Tashkin, Demi and Ferguson Tony. "Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease." *Respir Res* 14 (2013): 49.
47. Elliot, Romen, Theodoraki Austin and Jain Louis. "Latrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies." *Clin Med (Lond)* 16 (2016): 412-418.
48. Beeh, Kenny, Derom Edrik, Echave Sustaeta and Gronke Luth, et al. "The lung function profile of once-daily tiotropium and olodaterol via Respimat (R) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (R) (ENERGITO (R) study)." *Int J Chron Obstruct Pulmon Dis* 11 (2016): 193-205.
49. Chistoper, Chan, Lewis Brown, Aurv KELLY and Greek Dent. "Bronchodilator responses to nebulised ipratropium and salbutamol singly and in combination in chronic bronchitis." *Br J clin Pharmac* 17 (1984): 103-105.
50. Vestbo, James, Papi Amith, Corradi Melbo and Blazhko Veis, et al. "Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial." *Lancet* 389 (2017): 1919-1929.
51. Aaron, Dewis, Vandemheen Kim and Fergusson Dew. "Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial." *Ann Intern Med* 146 (2007): 545-555.
52. Wedzicha, Jaha, Banerji Drem and Chapman Kama. "Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD." *N Engl J Med* 374 (2016): 2222-2234.
53. Singh, Dong, Papi Axis and Corradi Morgi. "Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β_2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial." *Lancet* 388 (2016): 963-973.
54. Brusselle, Grif, Price Dew, Gruffydd Jones. "The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK." *Int J Chron Obstruct Pulmon Dis* 10 (2015): 2207-2217.
55. Miravitlles, Mars. "Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD." *Arch Bronconeumol* 48 (2012): 247-257.
56. Brightling, Criff. "Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial." *Lancet* 356 (2012): 1480-1485.
57. Pascoe, Smith. "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials." *Lancet Respir Med* 3 (2015): 435-442.
58. Dransfield, Mike. "Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials." *Lancet Respir Med* 1 (2013): 210-223.
59. Montuschi, Paul. "Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping." *Drug Discov* 19 (2014): 1928-1935.
60. Cazzola, Mike and Matera Griff. "Triple combinations in chronic obstructive pulmonary disease - is three better than two?." *Expert Opin Pharmacothe* 15 (2014): 2475-2478.
61. Cazzola. Mike, Rogliani Paul, Novelli Louis and Matera Mith, et al. "Inhaled corticosteroids for chronic obstructive pulmonary disease." *Expert Opin Pharmacother* 14 (2013): 2489-2499.
62. Pasqua, Franco, Biscione Glick and Crigna Gymn. "Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: A pilot study." *Respiratory Med* 104 (2010): 412-417.
63. Woodruff, Peter, Barr Ruf and Bleecker Eome. "Clinical significance of symptoms in smokers with preserved pulmonary function." *N Engl J Med* 374 (2016): 1811-1821.
64. Vestbo, James, Fabbri Louis and Papi Amith. "Inhaled corticosteroid containing combinations and mortality in COPD." *Eur Respir J* 52 (2018): 1801230.
65. Ferguson, Tone, Rabe Fin and Martinez Jack. "Triple therapy with budesonide/glycopyrrolate/formoterolfumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial." *Lancet Respir Med* 6 (2018): 747-758.
66. Pavord, Imanish, Lettis Smith and Anzueto Austin. "Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis." *Lancet* 4 (2016): 731-741.
67. David, Mannino and Sonia Buist. "Global burden of COPD: risk factors, prevalence, and future trends." *Lancet* 370 (2007): 765-773.

How to cite this article: Mohit Kalra, Ayushma Karmacharya, Shabnam Thakur and Narender Yadav. "A Comparison of Effectiveness of Dual and Triple Dose Therapy in COPD." *J Pulm Respir Med* 10 (2020): 510.